Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 ...

The Phase I trial is being conducted by the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands. In addition to ...

These activities are further supported by the in-vivo data demonstrating that both the NKG2A and CD3 arms contribute to the ...

LOTTE will manufacture antibody drug substance for Ottimo Pharma’s product at LOTTE’s Syracuse Bio Campus in New York.

Help is now there for those diagnosed with hard-to-treat blood cancers like leukemia and lymphoma, as new therapies are ...

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Researchers at the Max Planck Institute for Molecular Genetics have developed a novel synthetic micropeptide termed the ...

In this video, Paolo F. Caimi, MD, MBA, discusses research evaluating whether multi-virus specific T-cells could enhance ...

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most prevalent subtype, accounting ...

Roche's Hemlibra treatment for haemophilia A is one of its top-selling drugs, making almost $5 billion last year, and the ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...